ARTICLE | Product Development
Virtual leap
What Novartis expects to gain from Science 37’s virtual trial platform
March 10, 2018 2:44 AM UTC
Novartis AG’s decision to expand a collaboration with mobile technology and clinical trials management company Science 37 Inc. fits squarely within CEO Vasant Narasimhan’s oft-stated plans to use digital health to speed drug development.
The pharma has already test-driven Science 37’s cloud-based, mobile telemedicine platform within three Phase II clinical trials and has concluded the approach can speed recruitment -- at least in some indications...